Results 41 to 50 of about 5,752,243 (395)
Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation.
Cancer Discovery, 2021 The proteasome inhibitor bortezomib induces apoptosis in multiple myeloma cells and has transformed patient outcome. Using in vitro as well as in vivo immunodeficient and immunocompetent murine multiple myeloma models, we here show that bortezomib also ...
Annamaria Gullà +17 more
semanticscholar +1 more source
Living with multiple myeloma: A focus group study of unmet needs and preferences for survivorship care [PDF]
, 2017 Purpose: To describe the unmet informational, psychological, emotional, social, practical, and physical needs and preferences for posttreatment survivorship care of individuals living with multiple myeloma to inform the development of relevant ...
Bulsara, C +8 more
core +3 more sources
Experimental Hematology & Oncology, 2017 B cell lymphoma and multiple myeloma (MM) are the most common hematological malignancies which benefit from therapeutic monoclonal antibodies (mAbs)-based immunotherapies.
Li Zhang +4 more
doaj +1 more source
npj Precision Oncology, 2023 Optimal first-line treatment that enables deeper and longer remission is crucially important for newly diagnosed multiple myeloma (NDMM). In this study, we developed the machine learning (ML) models predicting overall survival (OS) or response of the ...
Sung-Soo Park +11 more
doaj +1 more source
The Emerging Role of Extracellular Vesicle-Associated RNAs in the Multiple Myeloma Microenvironment
Frontiers in Oncology, 2021 Multiple myeloma (MM) is a cancer of terminally differentiated plasma cells (PCs) that develop at multiple sites within the bone marrow (BM). MM is treatable but rarely curable because of the frequent emergence of drug resistance and relapse.
Jihane Khalife +4 more
doaj +1 more source
Multiple myeloma current treatment algorithms
Blood Cancer Journal, 2020 The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple new drugs, and emerging data from randomized trials to guide therapy.
S. Rajkumar, Shaji K. Kumar
semanticscholar +1 more source
Current Problems in Cancer, 2009 Multiple myeloma is a typical bone marrow neoplasia of the elderly. On radiographs it is often difficult to detect the typical osteolyses in early stages or in regions where overlying structures hamper image analysis. Osteoporosis may be a sign of tumor infiltration, but it is difficult to distinguish from senile osteoporosis.
Andrea, Baur-Melnyk +1 more
openaire +4 more sources
Prognostic and predictive biomarker developments in multiple myeloma
Journal of Hematology & Oncology, 2021 New approaches to stratify multiple myeloma patients based on prognosis and therapeutic decision-making, or prediction, are needed since patients are currently managed in a similar manner regardless of individual risk factors or disease characteristics ...
C. Wallington-Beddoe, Rachel L. Mynott
semanticscholar +1 more source
Blood Cancer Journal, 2022 Chimeric antigen receptor T cells (CAR T) are groundbreaking therapies but may cause significant toxicities including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and cytopenias.
Kevin Charles Miller +10 more
doaj +1 more source
Proteasome Inhibitors for the Treatment of Multiple Myeloma
Cancers, 2020 Use of proteasome inhibitors (PIs) has been the therapeutic backbone of myeloma treatment over the past decade. Many PIs are being developed and evaluated in the preclinical and clinical setting.
S. Ito
semanticscholar +1 more source